Upgrades Hold Buy X

PSNL Personalis

Needham

$8

Upgrades Neutral Buy X

PSNL Personalis

BofA Securities

$27 $23

Downgrades Buy Hold X

PSNL Personalis

Needham

Resumed Outperform X

PSNL Personalis

Cowen

Upgrades Perform Outperform X

PSNL Personalis

Oppenheimer

$28

Initiated Buy X

PSNL Personalis

Truist

$50

Downgrades Buy Neutral X

PSNL Personalis

BofA Securities

$40

Initiated Neutral X

PSNL Personalis

BofA/Merrill

$27

Initiated Outperform X

PSNL Personalis

Cowen

Initiated Overweight X

PSNL Personalis

Morgan Stanley

$28

Initiated Outperform X

PSNL Personalis

Oppenheimer

$29

PSNL  Personalis, Inc.

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.